van Houte Hans 4

What Happened

• Hans van Houte, Chief Financial Officer of Nurix Therapeutics (NRIX), sold a total of 14,055 shares in open-market transactions on May 5, 2026, generating approximately $233,319 in proceeds. The sales consisted of 13,473 shares at a weighted average price of $16.58 (proceeds $223,323) and 582 shares at a weighted average price of $17.18 (proceeds $9,996). These were sales (not purchases), which are typically routine liquidity events rather than a direct bullish signal.

Key Details

• Transaction date: 2026-05-05
• Trades:
  • 13,473 shares sold @ weighted avg $16.58 — proceeds $223,323 (price range reported $16.11–$17.10) [Footnotes F1, F2]
  • 582 shares sold @ weighted avg $17.18 — proceeds $9,996 (price range reported $17.11–$17.22) [Footnote F3]
• Total shares sold: 14,055; total proceeds: ≈ $233,319
• Reported footnote: at least one sale was effected pursuant to a Rule 10b5-1 trading plan (pre-arranged trading program) per the filing.
• Shares owned after the transaction: not provided in the excerpt supplied.
• Filing timeliness: no late-filing indication in the provided data.

Context

• Sales executed under a Rule 10b5-1 plan are pre-scheduled and are commonly used by insiders to sell shares for diversification or liquidity; they do not necessarily reflect the insider’s current view of the company’s prospects.
• For retail investors, purchases by insiders can be more indicative of confidence than routine plan-based sales; this filing documents a routine sale by the CFO rather than a new acquisition.